Moshe Weinstein CEO
Dr. Yaniv Dolev Founder & COO
Prof. Chezy Barenholz Inventor & Board Member
For more Information please visit:
The company is based on a patent-protected technology that was licensed from the Hebrew University of Jerusalem, the Technion Institute and Hadassah Medical Center. The Company’s lead product, MM-II, is a patent-protected intraarticular biolubricant injection for treatment of mild to moderate symptomatic knee osteoarthritis (OA). The company has been funded by RAD Biomed, PixVine Capital – a Singapore-based early stage VC fund, and Yissum – the technology transfer company of the Hebrew University of Jerusalem.